Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.

The Manufacturer Disclosure and Transparency Act requires drug manufacturers to inform the attorney general about any agreements that lead to delays in the release of generic medications. This aims to promote competition and ensure that affordable drug options are available to consumers. By increasing transparency, the bill seeks to prevent practices that keep drug prices high.

Supporters of the bill would argue that it is a crucial step towards making prescription drugs more affordable and accessible. By holding pharmaceutical companies accountable for their agreements, this legislation promotes fairness in the market and helps protect consumers from inflated prices.

Critics might argue that this bill could stifle innovation in the pharmaceutical industry by imposing burdensome reporting requirements. They may also claim that it could lead to unnecessary legal challenges that distract from the development of new medications and therapies.